Executive Director, QP2 Oncology
Merck & Co., Inc., United States
Pavan Vaddady currently serves as an Executive Director, Quantitative Pharmacology & Pharmacometrics - Oncology at Merck & Co., Inc., where he leads a team responsible for advancing Merck’s oncology portfolio efficiently across different milestones from first in human through registration. During his career, he led several early and late-stage development programs across multiple therapeutic areas both as a clinical pharmacologist and a pharmacometrician and applied model informed approaches to impact key drug discovery and development decisions. Prior to his current role, he was the Head of Advanced Pharmacometrics, Quantitative Clinical Pharmacology at Daiichi Sankyo, Inc., where he led a global team of scientists working on pharmacometrics deliverables for submissions along with advanced modeling projects involving multiple oncology assets. Pavan is passionate about teaching and mentoring and currently holds the position of Adjunct Professor at the University of Tennessee Health Science Center. He is also an elected Member of the Board of Trustees at the International Society of Pharmacometrics (ISoP), a non-profit organization dedicated to the advancement and promotion of pharmacometrics globally. He obtained his B. Pharm. (Hons.), and M. Pharm. from BITS Pilani, India and his Ph.D. in Pharmaceutical Sciences from the University of Tennessee Health Science Center, Memphis, USA.
Disclosure(s): Merck & Co., Inc.: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Challenges in characterizing treatment response in oncology - Pitfalls and solutions
Wednesday, November 13, 2024
9:00 AM – 10:30 AM MST
